FDA Clarifies Conditions for Mixing, Diluting or Repackaging Biologics

International Pharmaceutical Regulatory Monitor
A A
The FDA issued final guidance on approved biologics that are mixed, diluted or repackaged, noting when the agency will not take action against violations of its standard rules on product misbranding and false and misleading labeling.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor